When Weight Loss Stalls: Integrating Pharmacotherapy into a Functional Medicine Plan

Most patients who reach a weight loss plateau have been told the same thing for years. Eat less. Move more. Be patient. Try harder. The plateau is interpreted as a moral or behavioural failure, when it is most often a physiological one.

The body that has lost ten or fifteen percent of its mass through caloric restriction does not behave like the body that started. Adaptive thermogenesis reduces resting metabolic rate. Leptin levels fall, hunger hormones rise, and satiety signalling is blunted. Cortisol may rise. Sleep often deteriorates. Thyroid output can decline. The patient is now expected to maintain or extend the weight loss in a body that is more efficient at storing energy and more insistent in its drive to eat.

This is not a flaw of will. It is a defended physiology, and it deserves to be addressed as one.

A separate piece, Why Your Weight Loss Plateau Is a Metabolic Problem, Not a Willpower Problem, develops the underlying physiology in detail. This essay extends that argument into the practical question patients now face: when, how, and whether pharmacotherapy belongs in a functional medicine plan.

The Foundations Are Still the Foundations

Pharmacotherapy is an accelerant, not a substitute. The patient who arrives at a plateau without first establishing the foundations is not a candidate for medication; they are a candidate for the foundations.

The foundations remain unchanged. Resistance training to preserve and build lean mass — without it, weight loss tends to consist disproportionately of muscle, which lowers metabolic rate and worsens body composition. Cardiovascular conditioning to improve insulin sensitivity and oxidative capacity. Adequate protein intake — 1.2 to 1.6 grams per kilogram of body weight is the floor for most patients, higher in those who train and in older adults. Sleep restoration, because sleep deprivation alone disrupts every hormonal axis relevant to weight regulation. Stress management, because chronically elevated cortisol drives visceral adiposity and undermines satiety. And hormonal optimization, because suboptimal thyroid, sex hormone, or insulin signalling makes the foundations harder to sustain.

When these are in place and the body has adapted in ways that resist further progress, pharmacotherapy becomes a clinically reasonable consideration.

What Pharmacotherapy Can Do

The medications most relevant to a weight loss plateau in functional medicine practice fall into several classes.

GLP-1 receptor agonists. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) reduce appetite, slow gastric emptying, and improve glycemic control. They produce mean weight loss of fifteen to twenty percent of baseline body weight in clinical trials. In a patient who has stalled despite robust foundational work, GLP-1 therapy can break the plateau and allow further progress. The detailed framework for GLP-1 therapy — including monitoring, dosing, and the brand-versus-compounded question — is essential before starting.

Metformin. A long-established medication for type 2 diabetes, metformin improves insulin sensitivity and modestly reduces hepatic glucose output. The weight loss effect is small to moderate (typically 2 to 4 percent of body weight) but the metabolic benefit can be substantial in insulin-resistant patients. Metformin is well-tolerated, inexpensive, and has favourable longevity-associated data outside its diabetes indication.

Bupropion-naltrexone (Contrave). A combination medication approved for chronic weight management. It targets the central appetite and reward pathways. The effect size is smaller than GLP-1 therapy but the medication is oral, less expensive, and may suit certain patients particularly those whose plateau has a strong reward-eating or emotional component.

Topiramate (often combined with phentermine as Qsymia). Topiramate has appetite-suppressive effects and is used in some weight management protocols. The side effect profile, including cognitive effects, limits its use for many patients.

Thyroid optimization. Where suboptimal thyroid function is contributing — and it does in a meaningful subset of plateaued patients — appropriate thyroid evaluation and, when indicated, treatment can resolve a plateau that no other intervention will. The thyroid evaluation goes beyond TSH alone.

Sex hormone optimization. In men, low testosterone undermines metabolic recovery from weight loss attempts; restoring testosterone improves body composition outcomes. In women, the perimenopausal hormonal shift produces a body composition trajectory that is genuinely different from younger years; addressing this with appropriate BHRT can change the underlying environment.

Selective adjuncts. Berberine, inositol (particularly in PCOS), high-dose omega-3s, and certain other agents have specific roles. None has the effect size of GLP-1 therapy in the plateaued patient, but they may complement the protocol.

How to Decide

The decision to add pharmacotherapy to a functional medicine plan rests on several considerations.

Is the foundation actually in place? The patient who reports they are training but has not done resistance work, who is eating less but not enough protein, who is sleeping six hours and stressed, is not at a plateau yet. They are at the early stage of an inadequate intervention. Pharmacotherapy at this point delivers a transient effect that does not consolidate.

What does the metabolic data show? Fasting insulin, HOMA-IR, lipid panel with ApoB, hepatic enzymes, body composition, and waist circumference. A patient with an elevated fasting insulin and visceral adiposity has more to gain from GLP-1 therapy than a patient whose metabolic profile is already optimized. The data informs both whether and which.

What is the cardiovascular and oncologic context? Family history, personal history, age, and risk factors influence the choice. A patient with a family history of medullary thyroid carcinoma is not a GLP-1 candidate. A patient with significant pancreatic history requires careful assessment.

What is the goal? A patient seeking 5 percent weight loss has different options than a patient with metabolic syndrome seeking 15 to 20 percent. Pharmacotherapy is more appropriate when the magnitude of change required is substantial.

What is the long-term plan? Pharmacotherapy is not always indefinite, but cessation often produces partial regain. The conversation about long-term use, intermittent use, or titration to a maintenance dose belongs at the start, not after the prescription has been written.

Why Discontinuation Often Backfires

The most common failure mode in weight loss pharmacotherapy is not the medication but the discontinuation. A patient who loses 18 percent of body weight on semaglutide, stops the medication, and returns to prior dietary patterns will regain a substantial portion of the lost weight. The framing of the medication as a temporary tool — “to lose the weight, then go off it” — sets up this failure.

The more accurate framing, particularly for patients with metabolic dysfunction, is that the medication is part of the long-term metabolic strategy. The dose may be reduced over time. Discontinuation may be possible when the foundations are sufficient and the body composition target has been maintained for an extended period. But the medication should not be withdrawn at the moment the patient is most metabolically vulnerable.

This is the difference between weight loss and metabolic restoration. The first ends; the second continues.

The Vis Viva framework operationalizes this distinction. Sensus tracks the symptom and quality-of-life dimensions — appetite, energy, mood, satisfaction with the body — that signal whether the intervention is sustainable. Pulsus tracks the metabolic improvement that defines whether the intervention is producing the underlying biological change, not just the visible one. Virtus tracks the functional improvements — strength, cardiovascular fitness, body composition shift — that determine whether the result will last.

What to Ask Your Physician

If you have plateaued and are considering pharmacotherapy, several questions move the conversation forward.

What does my full metabolic and hormonal panel show, and which contributing factors are still modifiable through foundational work? Is my training adequate, and is my protein intake at the level required to preserve muscle? Is sleep well-restored? Are thyroid, sex hormones, and cortisol optimized? If pharmacotherapy is added, what is the monitoring schedule, the body composition tracking plan, and the long-term strategy?

The plateau is rarely the first sign of failure. It is most often the body’s most honest moment, asking for a more complete plan.

Continue Reading

If you found this useful, these related articles may deepen your understanding:

• Why Your Weight Loss Plateau Is a Metabolic Problem, Not a Willpower Problem
• Semaglutide and GLP-1 Therapy in Ontario: A Physician’s Framework
• Metabolic Syndrome in Your 40s

---

Dr. Handsun Xiao is a McGill trained physician (MD, CCFP) practicing functional medicine and bioidentical hormone therapy in Toronto, with virtual consultations available to patients across Ontario. He holds advanced BHRT certification through WorldLink Medical and IFM AFMCP training. Manus Solis offers physician led BHRT consultations with custom compounding through a dedicated Ontario compounding pharmacy partner Trutina. To learn more or book a virtual consultation, visit manussolis.ca.